Sponsored Links
| ARIAD Announces Preliminary Results From Ongoing Clinical Trial Of Its Investigational, Bcr-Abl Inhibitor In Drug-Resistant Chronic Myeloid Leukemia |
 |
 |
 |
| Medical News - Hematology | |||
|
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced preliminary clinical data from an ongoing Phase 1 clinical trial of its investigational, multi-targeted kinase inhibitor, AP24534, in patients with advanced hematological cancers. Read more: Blood / Hematology News From Medical News Today
|